plicamycin has been researched along with Disease Models, Animal in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, C; Zhao, J; Zhu, Y | 1 |
| Bharadwaj, S; Dutta, R; Green, R; Howell, M; Khalil, R; Mayilsamy, K; Mohapatra, S; Mohapatra, SS | 1 |
| Du, X; Huang, Q; Li, M; Ma, S; Xu, S; Yu, Q | 1 |
| Chen, C; Liu, R; Yang, R; Zhang, H; Zhi, X; Zhou, Z; Zou, T | 1 |
| Du, Y; Li, Z; Miao, J; Wei, C; Yan, Q; Zhang, W; Zhao, C; Zhou, Q | 1 |
| Guan, X; Jia, Z; Li, Q; Wang, L; Wei, D; Xie, K; Yao, J; Zhang, J | 1 |
6 other study(ies) available for plicamycin and Disease Models, Animal
| Article | Year |
|---|---|
Drug-Eluting Stent Targeting Sp-1-Attenuated Restenosis by Engaging YAP-Mediated Vascular Smooth Muscle Cell Phenotypic Modulation.
Topics: Angioplasty, Balloon; Animals; Apoptosis Regulatory Proteins; Cardiovascular Agents; Carotid Arteries; Carotid Artery Injuries; Carotid Stenosis; Cell Movement; Cell Plasticity; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Drug-Eluting Stents; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phenotype; Plicamycin; Prosthesis Design; Rabbits; Rats; Signal Transduction; Sp1 Transcription Factor; YAP-Signaling Proteins | 2020 |
Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Models, Animal; Female; Immune Checkpoint Inhibitors; Mice; Mice, Inbred C57BL; Plicamycin | 2021 |
Early activation of Egr-1 promotes neuroinflammation and dopaminergic neurodegeneration in an experimental model of Parkinson's disease.
Topics: Animals; Astrocytes; Calcium-Binding Proteins; CD11b Antigen; Cytokines; Disease Models, Animal; Dopamine; Early Growth Response Protein 1; Enzyme Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Microfilament Proteins; Neurodegenerative Diseases; Parkinsonian Disorders; Phosphopyruvate Hydratase; Plicamycin; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2018 |
Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Plicamycin; Sp1 Transcription Factor; Transcription, Genetic; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Mithramycin A Alleviates Cognitive Deficits and Reduces Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Cerebral Cortex; Cognition Disorders; Disease Models, Animal; Hippocampus; Male; Mice; Mice, Transgenic; Plicamycin; Sp1 Transcription Factor | 2016 |
Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Plicamycin; Sp1 Transcription Factor; Stomach Neoplasms; Transcription, Genetic; Vascular Endothelial Growth Factor A | 2008 |